Jan 06, 2018 at Targeted Oncology

Immune Checkpoint Inhibition in Esophagogastric Cancers

By : Targeted Oncology

An article in Targeted Oncology reviews the treatment strategy that’s changing the treatment landscape for gastric cancer: immunotherapy.

Read More
Jan 03, 2018 at OncLive

FDA Approvals in RCC and CML, Priority Review Designations in NSCLC and RCC, and More

By : OncLive

The European Union’s Committee for Medicinal Products for Human Use (CHMP) recommends the approval of Herzuma, a trastuzumab biosimilar, for treating HER2-positive gastric cancer patients. The CHMP’s opinion now goes to the full European Commission for final review.

Read More
Dec 20, 2017 at Human Pathology

BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers

By : Human Pathology

New research in Human Pathology finds BRCA1 and BRCA2 can be used as clinicopathological biomarkers to assess the prognosis of gastric cancer. 

Read More
Dec 19, 2017 at Cancer Network

Early Palliative Care Improves QOL for Lung and GI Cancer Patients

By : Cancer Network

A new study in the Journal of Clinical Oncology finds early palliative care leads to enhanced coping strategies and improved quality of life for gastric cancer patients.

Read More
Dec 13, 2017 at https://finance.yahoo.com/news/daiichi-sankyo-initiates-pivotal-phase-130000408.html?soc_src=mail&soc_trk=ma

Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Advanced Gastric Cancer

By : https://finance.yahoo.com/news/daiichi-sankyo-initiates-pivotal-phase-130000408.html?soc_src=mail&soc_trk=ma

A new phase 2 study in Japan and South Korea will evaluate the efficacy and safety of DS-8201 in ER2-expressing gastric cancer.

Read More
SHARE